top of page

News / Insights

News & Blog

Regulatory updates. Practical perspectives.
A clearer view of what comes next.

Blog: Blog2

[FDA Warning Letter Files] Paperwork Isn’t Enough — The Real Meaning Behind FDA’s Quality System (QSR) Warning

[FDA Warning Letter Files] Paperwork Isn’t Enough — The Real Meaning Behind FDA’s Quality System (QSR) Warning

[FDA Warning Letter Files] Paperwork Isn’t Enough — The Real Meaning Behind FDA’s Quality System (QSR) Warning

The FDA recently issued Warning Letters to two overseas medical device manufacturers, citing significant violations of the Quality System Regulation (QSR) . This action is not a mere administrative notification; it sends a powerful message that the FDA is actively stepping up scrutiny of overseas manufacturing operations and their capacity for effective quality system management. Both companies were found to have systemic failures in product testing and validation procedures,

FDA Warning Letter Files

Provision Consulting Group

Oct 30, 20253 min read

[FDA Warning Letter Files] Your Product Could Be a Target, Too.

[FDA Warning Letter Files] Your Product Could Be a Target, Too.

[FDA Warning Letter Files] Your Product Could Be a Target, Too.

A Look at U.S. Market Regulations Through a Recent FDA Warning Letter “An FDA warning letter? That's only for big corporations, right?”...

FDA Warning Letter Files

Provision Consulting Group

Oct 8, 20253 min read

FDA Labeling Errors: The Top Cause of U.S. Import Delays & Launch Failures

FDA Labeling Errors: The Top Cause of U.S. Import Delays & Launch Failures

FDA Labeling Errors: The Top Cause of U.S. Import Delays & Launch Failures

Have you ever had a seemingly perfect product unexpectedly delayed or detained at customs? One of the most common reasons for this is a...

FDA Regulations

Provision Consulting Group

Aug 4, 20252 min read

Your Device Is FDA-Cleared. Who Is Your U.S. Initial Importer?

Your Device Is FDA-Cleared. Who Is Your U.S. Initial Importer?

Your Device Is FDA-Cleared. Who Is Your U.S. Initial Importer?

4 days ago

FDA Finalizes Mandatory Cosmetics Recall Guidance: What K-Beauty Brands Entering the U.S. Should Know

FDA Finalizes Mandatory Cosmetics Recall Guidance: What K-Beauty Brands Entering the U.S. Should Know

FDA Finalizes Mandatory Cosmetics Recall Guidance: What K-Beauty Brands Entering the U.S. Should Know

Oct 30

Renew Your FDA Initial Importer Designation with Provision

Renew Your FDA Initial Importer Designation with Provision

Renew Your FDA Initial Importer Designation with Provision

Oct 16

OTC Drug Establishment Renewal: Time to Renew with Provision

OTC Drug Establishment Renewal: Time to Renew with Provision

OTC Drug Establishment Renewal: Time to Renew with Provision

Oct 16

FDA Food Facility Registration: 2026 Is a Renewal Year

FDA Food Facility Registration: 2026 Is a Renewal Year

FDA Food Facility Registration: 2026 Is a Renewal Year

Oct 14

FY2027 FDA Medical Device Registration Renewal: It’s Time to Renew with Provision

FY2027 FDA Medical Device Registration Renewal: It’s Time to Renew with Provision

FY2027 FDA Medical Device Registration Renewal: It’s Time to Renew with Provision

Oct 14

FDA’s FY2027 Medical Device Guidance Agenda: What Could It Mean for 510(k) Manufacturers?

FDA’s FY2027 Medical Device Guidance Agenda: What Could It Mean for 510(k) Manufacturers?

FDA’s FY2027 Medical Device Guidance Agenda: What Could It Mean for 510(k) Manufacturers?

Oct 7

Provision CEO Sung Kwon to Speak at Cosmoprof Asia Hong Kong 2026

Provision CEO Sung Kwon to Speak at Cosmoprof Asia Hong Kong 2026

Provision CEO Sung Kwon to Speak at Cosmoprof Asia Hong Kong 2026

Oct 2

FDA’s Purolea Warning Letter: What AI-Assisted GMP Documentation Means for Manufacturers

FDA’s Purolea Warning Letter: What AI-Assisted GMP Documentation Means for Manufacturers

FDA’s Purolea Warning Letter: What AI-Assisted GMP Documentation Means for Manufacturers

Sep 23

FDA Form 483 Response Is Not the Finish Line: What the Bausch & Lomb Warning Letter Reveals About CAPA

FDA Form 483 Response Is Not the Finish Line: What the Bausch & Lomb Warning Letter Reveals About CAPA

FDA Form 483 Response Is Not the Finish Line: What the Bausch & Lomb Warning Letter Reveals About CAPA

Sep 19

FDA Sunscreen Regulatory Update: PABA and Trolamine Salicylate Removed from OTC Monograph M020

FDA Sunscreen Regulatory Update: PABA and Trolamine Salicylate Removed from OTC Monograph M020

FDA Sunscreen Regulatory Update: PABA and Trolamine Salicylate Removed from OTC Monograph M020

Sep 16

What Does It Mean When Torriden Delegates U.S. Regulatory Compliance to Provision Consulting Group?

What Does It Mean When Torriden Delegates U.S. Regulatory Compliance to Provision Consulting Group?

What Does It Mean When Torriden Delegates U.S. Regulatory Compliance to Provision Consulting Group?

Sep 9

Introducing the Provision Client Portal (Beta): A New Way to Work With Us

Introducing the Provision Client Portal (Beta): A New Way to Work With Us

Introducing the Provision Client Portal (Beta): A New Way to Work With Us

Sep 9

Why Provision Built R.I.S.E. Turning 50,000+ Real Regulatory Cases into Regulatory Intelligence

Why Provision Built R.I.S.E. Turning 50,000+ Real Regulatory Cases into Regulatory Intelligence

Why Provision Built R.I.S.E. Turning 50,000+ Real Regulatory Cases into Regulatory Intelligence

Aug 28

FY2027 FDA Medical Device User Fees Finalized: MDUFA V’s Final Year and What You Need to Know

FY2027 FDA Medical Device User Fees Finalized: MDUFA V’s Final Year and What You Need to Know

FY2027 FDA Medical Device User Fees Finalized: MDUFA V’s Final Year and What You Need to Know

Aug 24

Provision Consulting Group Speaks at ACI Conference on K-Beauty and U.S. Regulatory Challenges

Provision Consulting Group Speaks at ACI Conference on K-Beauty and U.S. Regulatory Challenges

Provision Consulting Group Speaks at ACI Conference on K-Beauty and U.S. Regulatory Challenges

Aug 18

MDUFA VI: Why FDA Device Reviews Are Getting Tougher, Not Faster

MDUFA VI: Why FDA Device Reviews Are Getting Tougher, Not Faster

MDUFA VI: Why FDA Device Reviews Are Getting Tougher, Not Faster

Aug 14

Trapped in Customs: The Hidden Triggers Behind FDA Import Alerts for Medical Devices

Trapped in Customs: The Hidden Triggers Behind FDA Import Alerts for Medical Devices

Trapped in Customs: The Hidden Triggers Behind FDA Import Alerts for Medical Devices

Aug 3

Container Stuck at a U.S. Port — What Triggers an FDA Import Alert for Food and Supplements

Container Stuck at a U.S. Port — What Triggers an FDA Import Alert for Food and Supplements

Container Stuck at a U.S. Port — What Triggers an FDA Import Alert for Food and Supplements

Jul 27

FDA US Agent: What Happens When They Go Silent — and You Picked Them on Price

FDA US Agent: What Happens When They Go Silent — and You Picked Them on Price

FDA US Agent: What Happens When They Go Silent — and You Picked Them on Price

Jul 20

What Huons' FDA Warning Letter Reveals About Today's CGMP Enforcement

What Huons' FDA Warning Letter Reveals About Today's CGMP Enforcement

What Huons' FDA Warning Letter Reveals About Today's CGMP Enforcement

Jun 30

FDA 510(k) Clearance: Why a "Complete" eSTAR Doesn’t Guarantee Approval

FDA 510(k) Clearance: Why a "Complete" eSTAR Doesn’t Guarantee Approval

FDA 510(k) Clearance: Why a "Complete" eSTAR Doesn’t Guarantee Approval

Jun 29

FDA Sunscreen Ingredient Update: Bemotrizinol Added to the U.S. OTC Monograph

FDA Sunscreen Ingredient Update: Bemotrizinol Added to the U.S. OTC Monograph

FDA Sunscreen Ingredient Update: Bemotrizinol Added to the U.S. OTC Monograph

Jun 23

A Kimchi Brand Just Got Recalled. The Culprit? Anchovies.

Jun 15

KOTRA x Provision Consulting Group to Support Korean Companies at BIO International Convention San Diego

KOTRA x Provision Consulting Group to Support Korean Companies at BIO International Convention San Diego

KOTRA x Provision Consulting Group to Support Korean Companies at BIO International Convention San Diego

Jun 11

The FDA is Cracking Down on Sunscreen Factories—Is Yours Truly Ready?

The FDA is Cracking Down on Sunscreen Factories—Is Yours Truly Ready?

The FDA is Cracking Down on Sunscreen Factories—Is Yours Truly Ready?

Jun 1

FDA-Compliant, Yet Still Sued? The Labeling Risks U.S.-Bound Brands Often Miss

FDA-Compliant, Yet Still Sued? The Labeling Risks U.S.-Bound Brands Often Miss

FDA-Compliant, Yet Still Sued? The Labeling Risks U.S.-Bound Brands Often Miss

May 15

Medical Devices Have IDs Too — The FDA UDI Guide for U.S. Market Entry

Medical Devices Have IDs Too — The FDA UDI Guide for U.S. Market Entry

Medical Devices Have IDs Too — The FDA UDI Guide for U.S. Market Entry

May 4

MoCRA Insight: Same Ingredients, Same Formula — Different FDA Interpretations

MoCRA Insight: Same Ingredients, Same Formula — Different FDA Interpretations

MoCRA Insight: Same Ingredients, Same Formula — Different FDA Interpretations

Apr 24

Longevity and In & Out Beauty: What K-Beauty Brands Are Missing in the U.S. Market

Longevity and In & Out Beauty: What K-Beauty Brands Are Missing in the U.S. Market

Longevity and In & Out Beauty: What K-Beauty Brands Are Missing in the U.S. Market

Apr 13

'Magnif's make p:rem', a K-Beauty Brand, Just Landed at Sephora. Here's What Made It Possible.

Mar 31

Why Your K-Clinic Launch Could Trigger an FDA "Drug Claim" — MoCRA Strategies for 2026

Why Your K-Clinic Launch Could Trigger an FDA "Drug Claim" — MoCRA Strategies for 2026

Why Your K-Clinic Launch Could Trigger an FDA "Drug Claim" — MoCRA Strategies for 2026

Mar 24

One Sunscreen Could Land You on FDA's Blacklist — Have You Checked Your OMUFA FY2026 Status?

One Sunscreen Could Land You on FDA's Blacklist — Have You Checked Your OMUFA FY2026 Status?

One Sunscreen Could Land You on FDA's Blacklist — Have You Checked Your OMUFA FY2026 Status?

Mar 13

Two More Digits. A Lot More Work. — FDA's NDC Format Change Explained

Two More Digits. A Lot More Work. — FDA's NDC Format Change Explained

Two More Digits. A Lot More Work. — FDA's NDC Format Change Explained

Mar 6

K-Beauty FDA Compliance: Why 'Marketing' Is No Longer Enough in the U.S. Market

K-Beauty FDA Compliance: Why 'Marketing' Is No Longer Enough in the U.S. Market

K-Beauty FDA Compliance: Why 'Marketing' Is No Longer Enough in the U.S. Market

Feb 24

[Cosmoprof Miami 2026] K-Beauty: Moving Beyond ‘Registration’ to ‘Regulatory Strategy’

[Cosmoprof Miami 2026] K-Beauty: Moving Beyond ‘Registration’ to ‘Regulatory Strategy’

[Cosmoprof Miami 2026] K-Beauty: Moving Beyond ‘Registration’ to ‘Regulatory Strategy’

Feb 16

2 3 4 5

From insight to action

What does this mean for your business?

Talk through your FDA questions with a team that stays close to the details.

Start a conversation ↗

bottom of page